Cencora Prices $500 Million 3.950% Senior Notes Due 2029, $500 Million 4.250% Senior Notes Due 2030, $500 Million 4.600% Senior Notes Due 2033, $1.0 Billion 4.900% Senior Notes Due 2036 and $500 Million 5.650% Senior Notes Due 2056Business Wire • 02/10/26
Cencora Stock Down Despite Q1 Earnings Beat, Gross Margin ImprovesZacks Investment Research • 02/04/26
Cencora (COR) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 02/04/26
Exploring Analyst Estimates for Cencora (COR) Q1 Earnings, Beyond Revenue and EPSZacks Investment Research • 01/30/26
Can Specialty and International Momentum Support Cencora's Q1 Results?Zacks Investment Research • 01/29/26
Curant Rare Announces Collaboration with Cencora to Support Commercialization of Rare and Orphan Drug ProductsBusiness Wire • 01/22/26
Cencora, Inc. (COR) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26
3 Medical Supplies Stocks That Beat the Market Despite Macro HeadwindsZacks Investment Research • 01/12/26
Cencora Announces Date and Time for First Quarter Fiscal 2026 Earnings ReleaseBusiness Wire • 01/06/26
Cencora to Acquire OneOncology to Expand Community Oncology SolutionsZacks Investment Research • 12/19/25
Cencora Accelerates OneOncology Acquisition, Extending Solutions Offering for Community OncologyBusiness Wire • 12/15/25
Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 12/09/25
Cencora Enhances Global Pharmaceutical Logistics Services, Cold Chain CapabilitiesBusiness Wire • 12/03/25